Full-Time
Chief of Staff
Updated on 9/3/2026
Integrated Biosciences
11-50 employees
AI-driven synthetic biology therapeutics discovery
No salary listed
San Carlos, CA, USA
In Person
In-office role based in Redwood City, CA. Visa sponsorship available where applicable.
Bachelor's
 Business & Strategy (1) |
|---|
Get referred to Integrated Biosciences
See people who can refer or advise you
- B.A. or B.S. degree and 3 to 5+ years of experience in a similar role
- Willingness to work hard in service of solving the biology of aging
- Excellent interpersonal and time management skills, with a proven track record of strong communication and decision-making support
- Ability to learn and adapt quickly as part of a growing company and team
- Act as a strategic partner to the CEO and executive team, managing high-priority initiatives, synthesizing information for decision-making, and ensuring alignment across scientific, operational, and business functions
- Drive cross-functional projects and company-wide priorities, including milestone planning and tracking, vendor and budget management, and process improvements to support rapid growth and efficient scaling
- Design and prepare around the company’s operating cadence, including all-hands meetings, offsites, and workflows internally and externally
- Coordinate executive communications and strategic events and media
- Prepare materials for board meetings, investor updates, and fundraising efforts, while managing relationships with key stakeholders (e.g., VCs, partners, advisors)
- Aid in managing company representation for the executive team and assist with alliance management
- Experience in a high-impact role such as Chief of Staff, strategy, operations, management consulting, or operating leadership in the biotechnology, pharmaceutical, or tech sectors
- Experience working directly with founders or C-level executives on strategic and operational priorities
- Experience with drug discovery and/or AI-enabled R&D platforms
- Experience building productivity and business operation tools leveraging cutting edge AI and coding tools
Integrated Biosciences develops therapies for age-related diseases using a platform that blends synthetic biology, AI-driven small-molecule drug discovery, optogenetics, chemistry, and computation. The platform helps scientists understand complex cellular stress biology and identify compounds that modulate stress responses linked to neurodegeneration, cancer, and diabetes. Drugs are discovered and developed through research and development efforts, with the goal of bringing new therapeutics to patients. Unlike traditional pharma approaches that rely on a single method, Integrated Biosciences combines biology engineering, machine learning, and precision chemistry to accelerate the discovery and optimization of drug candidates.
Company Size
11-50
Company Stage
Late Stage VC
Total Funding
$85.6M
Headquarters
San Carlos, California
Founded
2022
Get referred to Integrated Biosciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 2026 fundraising reports $68.4 million, extending runway after the 2024 $17.2 million seed.
- Tony Wu joined the Scientific Advisory Board in February 2026, adding frontier-model expertise.
- The company touts sixfold senolytic hit-rate gains and multi-year LVMH research support.
What critics are saying
- Integrated Biosciences still has no disclosed clinical candidate or human trial by September 2026.
- The platform depends on unproven AI biology translation; failures before 2027 erase valuation.
- LVMH and seed financing do not guarantee drug approvals, and commercialization remains years away.
What makes Integrated Biosciences unique
- Jim Collins, David MacMillan, and Daniel Anderson anchor a rare aging-drug discovery bench.
- Optogenetics plus AI enables precise transcriptome control, unlike standard virtual screening.
- LVMH Recherche partnership broadens the platform into beauty, not only therapeutics.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
401(k) Company Match
Company Equity
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -5%2 year growth
↑ 6%Five new SEC Form D filings hit EDGAR this week, together raising $771.8M. Here’s the roundup, scored for B2B sales relevance by Funding…
Integrated Biosciences has secured $17.2 million in seed financing led by Sutter Hill Ventures to develop therapeutics targeting age-related diseases. The company combines synthetic biology and artificial intelligence to enhance drug discovery, employing techniques including optogenetics for precise cellular data control. The funding will accelerate development of the company's drug pipeline, enhance its platform and support commercialisation efforts. Integrated Biosciences benefits from advisors with expertise in medical engineering, systems biology and drug development, providing insight into translational medicine. The company's approach uses machine learning alongside synthetic biology to innovate the drug discovery process for age-related conditions.
Integrated Biosciences, a biotechnology company using optogenetics, chemistry and AI to discover therapeutics for age-related diseases, has appointed Tony Wu, co-founder of xAI, to its Scientific Advisory Board. Wu played a key role in building Grok, xAI's reasoning and agentic AI model, and scaling the Colossus supercomputer cluster. His expertise in large-scale model training and AI applications to scientific discovery will support Integrated Biosciences' platform, which has demonstrated sixfold improvements in hit rates for senolytic compounds and breakthroughs in virtual staining and biological age inference from microscopy. The appointment strengthens the company's advisory board, which includes experts in ageing biology, drug discovery and a Nobel Prize winner in chemistry. Integrated Biosciences is based in Redwood City, California.
Integrated Biosciences has appointed Daniel J. Anderson as chief scientific officer. Anderson joins from Eikon Therapeutics, where he served as CSO and managed a team of 130 scientists leading discovery and translational research efforts. In his new role, Anderson will oversee scientific strategy and pipeline development at Integrated Biosciences, which combines synthetic biology, chemistry and AI to discover small-molecule therapeutics for age-related diseases. He previously held positions at Recursion Pharmaceuticals, Cleave Biosciences and Genentech, advancing 10 programmes into clinical trials. Max Wilson, co-founder of Integrated Biosciences, has moved to chief technology officer, where he will focus on advancing the company's technology platform, including AI-enabled discovery systems and high-throughput biological screening.
Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics f